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Background: Making peptide pharmaceuticals involves challenging processes where many barriers, which include
production and manufacture, need to be overcome. A non common but interesting research area is related to
peptides with intracellular targets, which opens up new possibilities, allowing the modulation of processes
occurring within the cell or interference with signaling pathways. However, if the bioactive sequence requires
fusion to a carrier peptide to allow access into the cell, the resulting peptide could be such a length that traditional
production could be difficult. The goal of the present study was the development of a flexible recombinant
expression and purification system for peptides, as a contribution to the discovery and development of these
potentially new drugs.
Results: In this work, a high throughput recombinant expression and purification system for production of cell
penetrating peptides in Escherichia coli has been designed and implemented. The system designed produces target
peptides in an insoluble form by fusion to a hexahistidine tagged ketosteroid isomerase which is then separated by
a highly efficient thrombin cleavage reaction procedure. The expression system was tested on the anticancer
peptides p53pAnt and PNC27. These peptides comprise the C-terminal region and the N-terminal region of the
protein p53, respectively, fused by its carboxyl terminal extreme to the cell penetrating peptide Penetratin. High
yields of purified recombinant fused peptides were obtained in both cases; nevertheless, thrombin cleavage
reaction was successful only for p53pAnt peptide release. The features of the system, together with the procedure
developed, allow achievement of high production yields of over 30 mg of highly pure p53pAnt peptide per g of
dry cell mass. It is proposed that the system could be used for production of other peptides at a similar yield.
Conclusions: This study provides a system suitable for recombinant production of peptides for scientific research,
including biological assays.
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Thrombin cleavageBackground
The study of peptides as therapeutic molecules has gener-
ated great interest in the pharmaceutical industry due to
their low toxicity, high specificity and high biological activ-
ity [1]. However, there are still many challenges inherent
to peptide production, particularly related to synthesis,
scale-up and purification. At present the main method of
peptide production is chemical synthesis. This involves* Correspondence: vidrodri@ing.uchile.cl
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unless otherwise stated.sequential addition of each amino acid to complete the de-
sired sequence, which leads to an accumulative reduction
in performance [2,3]. Moreover, the extremely large con-
sumption of solvents and production of waste, make it a
non environmentally friendly method [3].
As an alternative synthesis method, recombinant pro-
duction of peptides has become a good choice for produc-
tion of long peptides (longer than 25 aa), mainly because
it offers a good combination of cost-effectiveness, scalabil-
ity and sustainability [4,5].
An interesting peptide research area is related to the
study of therapeutic peptides with intracellular targets.ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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opment of a disease are not limited to extracellular
signaling. They also involve complex networks with
intracellular regulation pathways which are worthy of
exploration. However, this type of research has been lim-
ited, in part, by the low permeability of the cell mem-
brane to most macromolecules [6]; less than 10% of
peptide candidates entering clinical studies bind intracel-
lular targets [7]. A common strategy is to fuse a bio-
active molecule to a carrier peptide (Cell Penetrating
Peptide, CPP). These are cationic peptides with the abil-
ity to get into the cells and it has been demonstrated
that they can mediate intracellular delivery of covalently
bonded molecules, amongst them bioactive peptide se-
quences [8-13]. In this case, the fusion usually results in
a final peptide longer than 30 amino acids, making trad-
itional production difficult. Despite this, currently, of the
peptides in Phase II studies, there are three bioactive
peptides that incorporate a CPP sequence to enter the
cells [7]. Producing these peptides efficiently in order to
minimize the production cost by means of a recombin-
ant peptide production system, could make these pep-
tides more attractive for the pharmaceutical industry.
Biosynthetic production of peptides in Escherichia coli
by direct expression may lead to cytoplasmic degrad-
ation of the product, poor recovery yields or to generate
host toxicity. To overcome these problems, expression
systems often produce recombinant peptides as fused
peptides, bound to a protein with specific properties
[14,15] or as tandem repeats of the peptide sequence
[16]. These strategies require a subsequent hydrolysis
step to release the target peptide sequence. Usually,
chemical hydrolysis on methionine residues, on Asp^Pro
[15] or on Asn^Gly [16] with cyanogen bromide (CNBr),
formic acid or hydroxilamine, respectively, is used. These
reagents are highly toxic, so alternatively, enzymatic prote-
olysis can be used for separation by including specific rec-
ognition sequences of common proteases. However, the
latter has the disadvantage of being more expensive than
chemical proteolysis.
A noteworthy peptide production method is the pET-
31b(+) vector system for E. coli, from Novagen. This al-
lows cloning of the target peptide sequence downstream
of a ketosteroid isomerase (KSI) coding sequence and
upstream of a polyhistidine tag sequence. The KSI pro-
tein is highly insoluble, so directs the expression of the
fusion protein to produce inclusion bodies, preventing
polypeptide degradation during bacterial expression and
the polyhistidine tag allows purification of the fused pep-
tide by nickel affinity chromatography. The peptide se-
quence must be flanked with methionine residues and
could be cloned as tandem repeated sequence, then the
target peptide could be separated from the partner pro-
tein by chemical hydrolysis with CNBr. Finally, targetpeptides are recovered from the cleavage product by
chromatographic separation. High peptide productivity
of more than 50 mg per liter of a culture at a density of
2.5 g of cells per liter has been achieved using this
method [17]. Nevertheless, the target peptide sequences
are limited to those not containing methionine residues
and the process involves working with a hazardous re-
agent. Moreover, chemical hydrolysis with CNBr leads to
peptide monomers with a C-terminal homoserine lac-
tone and could lead to chemical modifications on amino
acid side chains on the target peptide [18]. Some at-
tempts have been made to modify this system to, alter-
natively, liberate the target peptide through enzymatic
reactions. However, these methods have required the use
of high amounts of enzyme to achieve an efficient prote-
olysis process, increasing the production cost and thus,
limiting their use [19,20].
The aim of this work is the design and implementation
of a flexible method for an efficient recombinant bacterial
expression and purification system for production of po-
tentially therapeutic peptides with intracellular targets.
The expression system developed in Escherichia coli has
been designed to be flexible in expressing and purifying
potentially therapeutic peptides fused to the cell penetrat-
ing peptide Penetratin (KKWKMRRNQFWVKVQRG)
[21,22]. The system includes a fusion partner which com-
prises a hexahistidine-tagged ketosteroid isomerase do-
main and a thrombin cleavage site, in order to allow a
high expression yield and facilitate purification, and to lib-
erate the peptide from the KSI protein, respectively. Un-
like the system described above, the procedure designed
allows a high yield production process at a relatively low
cost, avoiding the use of hazardous reagents.
The expression system was tested on the anticancer
peptides p53pAnt and PNC27. The p53pAnt peptide
comprises the C-terminal region of the protein p53, as
bioactive sequence, fused by its carboxyl terminal ex-
treme to the cell penetrating peptide Penetratin, as
transporter sequence, (GSRAHSSHLKSKKGQSTSRHKK
WKMRRNQFWVKVQRG). It has been shown that this
peptide selectively induces apoptosis in cancer cells with
mutated or overexpressed p53 through p53-dependent
processes [23,24]. The anticancer peptide has been
tested in vitro in different cell types, such as colon can-
cer cells [23,25], breast cancer [24,25], lung [25] and
lymphoma [23]. Furthermore, it has been reported to se-
lectively produce necrosis in prostate cancer cells [26]
and that it is able to selectively induce cell death by
apoptosis in vivo, in a model of brain tumor (glioma) in
rats [27]. The PNC27 peptide comprises the mdm-2
binding domain of the p53 protein (residues 12–26) con-
taining a C-terminal Penetratin sequence as carrier
(PPLSQETFSDLWKLLKKWKMRRNQFWVKVQRG) [28].
Unexpectedly, this peptide was found to induce selective
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it has an amphipatic structure [32,33] which allows it
to integrate into the cell membrane forming pores, produ-
cing membrane disruption and cell death by a p53-
independent mechanism [29,32,34]. The selectivity on
tumor cells would be given by the presence of mdm-2 on
the plasma membrane of these cells [35,36], which is re-
lated to the role of mdm-2 in E-cadherin ubiquitination
and degradation [36]. Thus, in non-tumor cells, PNC27 en-
ters the cell, but in cancer cells it is retained in the mem-
brane due to its affinity for mdm-2, and forms pores [35].
This paper shows the design of a system for producing
high yield fused recombinant peptides and a procedure for
efficient enzymatic cleavage to liberate the target peptides,
which allowed production of highly pure p53pAnt pep-
tide. Although the system failed at the proteolysis step in
PNC27 peptide production, it is proposed that it could be
potentially used for the production of other peptides.
Results
Design and construction of a pET31HT expression vector
Modifications made to pET-31b(+) allowed setting up
the pET31HT vector. It comprises a KSI gene which
contains an N-terminal hexahistidine tag-coding se-
quence to facilitate purification. A thrombin recognition
site was positioned downstream of the KSI sequence,
followed by AvrII and PacI restriction enzyme sites
which compose the cloning site for the target peptide
coding sequence. The AvrII site encodes the last two
amino acids of the thrombin recognition site and the
PacI site, which was designed to remain downstream of
the cloned sequence, includes the stop codon for transla-
tion. Thus, the design allows cloning different potentially
therapeutic cell penetrating peptides between these re-
striction enzyme sites and subsequently to separate them
from the KSI fusion partner leaving no additional residues
from the original peptide sequence. A schematic represen-
tation of the construct is shown in Figure 1.
Expression and purification of recombinant fused
peptides
The peptide-encoding sequences were cloned into the ex-
pression vector pET31HT by the procedure described in
Methods. The resulting vectors pET31HT-p53pAnt and
pET31HT-PNC27, confirmed by DNA sequencing, were
transformed into the expression host Escherichia coliFigure 1 Schematic diagram of the expression vector pET31HT. Green
purple: thrombin recognition site coding sequence; light blue: cloning site
in brown.BL21(DE3). A transformant colony of every construct was
selected and grown at 37°C in LB medium containing 100
μg/mL ampicillin and induced by IPTG addition. A colony
harboring the pET31HT vector was used as induction
control. As shown in Figure 2 recombinant proteins KSI,
KSI-p53pAnt and KSI-PNC27 were in an insoluble form
and accounted for about 40% of the total protein. The
productivity of the KSI control protein and the fused pep-
tides was almost 20% of the dry cell mass. Recombinant
proteins were purified from the insoluble fraction by Ni+2
affinity chromatography in denaturing conditions. About
95% of the recombinant protein was purified in a single
elution fraction of equal volume to the loaded sample. It
was observed that it is possible to recover all the recom-
binant protein bound to the resin by additional elutions of
smaller volumes which then could be combined with the
main elution. The purity of the eluted recombinant pro-
tein was estimated by SDS-PAGE analysis and it was de-
termined to exceed 90% (Figure 2).
Proteolytic cleavage and purification of recombinant
peptides
Precipitation of purified fused peptides through dilution
allows recovery of practically all of the protein, with no
loss detected in the supernatant by SDS-PAGE analysis.
The precipitated protein was solubilized in cleavage buf-
fer. Thrombin was added to the sample at a ratio of 0.35
unit of enzyme per mg of protein and incubated at 23°C
with gentle shaking. Figure 3 shows the progress of the
enzymatic cleavage reaction for p53pAnt fused peptide.
Enzymatic cleavage of the fused peptide achieved about
60% digestion in 6 hours and about 80% digestion when
the reaction was extended to 48 hours. When the reac-
tion rate decreased and the curve became asymptotic,
the addition of another equal amount of thrombin in-
creased digestion to 95% of the fused peptide.
In the case of KSI-PNC27 recombinant protein, unex-
pectedly, incubation with thrombin protease did not
cleave the fusion protein since no peptide hydrolysis
product was detected on SDS-PAGE analysis.
The digestion product of KSI-p53pAnt was loaded
onto a nickel-nitrilotriacetic acid (Ni-NTA) agarose col-
umn. The flow-through containing the p53pAnt peptide
was collected. The column was washed with cleavage
buffer to recover most of peptide in solution. A final
wash with elution buffer was made in order to analyze: Polyhistidine tag coding sequence; red: ketosteroid isomerase gene;
restriction enzymes. Start and stop translation codons are crowned
Figure 2 SDS-PAGE analysis of recombinant protein expression in E. coli BL21(DE3). SDS-PAGE 12.5% T, 3% C; Tris-Glycine buffer system.
M: Molecular weight marker; 1: KSI (14.73 kDa); 2: KSI-p53pAnt (19.09 kDa); 3: KSI-PNC27 (18.69 kDa).
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erated KSI protein and the uncleaved KSI-p53pAnt fused
peptide were retained by the column because both have
a N-terminal polyhistidine tag. However, about 15% of
the peptide was also bound to the column and was not
eluted by the cleavage buffer wash. A summary of
the purification procedure is shown in Table 1. Overall
productivity obtained was more than 30 mg of peptide
per g of dry cell mass.
The purity of the resulting peptide was determined on
SDS-PAGE analysis visualized by silver staining and a
high molecular weight contaminant protein was detected
(Figure 4A). In order to estimate the ratio between the
peptide and this protein by densitometry analysis, 2 mg
of purified peptide were loaded onto a single lane on a
second SDS-PAGE gel and was visualized by Coomasie
staining, but the contaminant band was not detected
(Figure 4B). Assuming that this band is right at the limit
of detection of the Coomasie staining (0.1 μg for a single
protein band [37]), the purity of the recombinant pep-
tide was estimated as at least 95%.
A sample of the purified p53pAnt peptide was ana-
lyzed by Matrix Assisted Laser Desorption Ionization
Time-of-Flight (MALDI-TOF) mass spectrometry. Thetheoretical m/z average ratio of the p53pAnt peptide is
4,435. The spectrum obtained contained the expected sig-
nal and the signal corresponding to the doubly protonated
molecule (m/z = 2,218) (Figure 5), indicating that the re-
sultant peptide actually corresponds to p53pAnt. No sig-
nal attributable to the detected contaminating protein
shown in Figure 4A was detected.
Discussion
The system presented in this paper was developed as an
alternative tool to be used in research and development of
new peptide drugs, especially for those with intracellular
therapeutic targets. The procedure requires the attach-
ment of the bioactive sequence to the cell penetrating
peptide, Penetratin. This sequence allows entry into the
cell and delivery to the intracellular target. The whole
oligonucleotide sequence must be codon optimized and
cloned in the designed vector.
In order to protect the peptides from enzymatic deg-
radation during production and thus to achieve higher
yields, the system directs the expression of the cloned
peptide to produce inclusion bodies by its fusion to the
insoluble protein ketosteroid isomerase. Inclusion bodies
are stable against proteolysis and also have the advantage
Figure 3 Thrombin cleavage reaction progress at 23°C and 0.35 units of enzyme per mg of protein. A: Reaction curve. The arrow
indicates addition of an equal amount of thrombin. B: SDS-PAGE 10% T, 3% C; Tris-Tricine buffer system. Different species are indicated as K-P:
KSI-peptide fused peptide; K: KSI partner protein; P: Peptide. M: Molecular weight marker; lanes 1–9: samples of the reaction at different times in
hours. Lane 1: 0 h; lane 2: 2 h; lane 3: 4 h; lane 4: 8 h; lane 5: 20 h; lane 6: 30 h; lane 7: 48 h; lane 8: 72 h; lane 9: 96 h.
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more, they usually have high recombinant protein con-
centration and low relative amounts of contaminants. As
a result, the procedure allows an initial recovery of the
recombinant fused peptide with relatively high purity of
more than 75% of the inclusion body protein content.Table 1 Purification of KSI–p53pAnt fused peptide and
p53pAnt peptide, overexpressed in E. coli BL21(DE3)








Total protein extract n.d n.d 43* 100
Inclusion bodies n.d n.d 79* -
First affinity
chromatography
184** 43 90* -
Precipitation recovery 184 43 - 100*
Thrombin cleavage - - - 95*
Second affinity
chromatography
- 34** 95 85*
Data per g of dry cell weight.
Experiments n.d., not determined.
*Determined by SDS-PAGE gels densitometry analysis.
**Determined by Bradford assay.
Figure 4 Purified p53pAnt peptide. SDS-PAGE 10% T, 3% C;
Tris-Tricine buffer system. M: Molecular weight marker; 1: p53pAnt.
A: 0.125 μg of peptide visualized with silver staining. Blue arrow indicates
a contaminant protein band. B: 2 μg of peptide visualized with
Coomasie staining. The contaminant protein band is not visualized.
Figure 5 MALDI-TOF mass spectrum of the purified p53pAnt peptide.
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peptides attached to the KSI protein by immobilized
metal affinity chromatography (IMAC) by including a
polyhistidine tag. Then, the fused peptide construct is
bound to the column and eluted, to later be subjected to
enzymatic cleavage to release the target peptides. Finally,
the digestion product is loaded onto a second IMAC
chromatography, where the partner protein, the non-
cleaved protein and any impurity present after the first
chromatography will bind to the column, allowing ob-
tention of a highly pure peptide in the flow-through.
Unlike other common systems that use KSI as a fusion
protein partner for recombinant production of peptides,
the designed system allowed production of peptide se-
quences without restriction on the presence of any amino
acidic residue and without using acid conditions or toxic
reagents such as hydroxylamine or cyanogen bromide. In-
stead, this system incorporates a thrombin recognition site
strategically located so that the peptide is separated from
the KSI protein without leaving any additional residues.Of common proteases, the lower cost of cleaving fusion
proteins, per mg, is obtained using thrombin [15]. More-
over, the designed procedure for the hydrolysis reaction
allowed recovery of the p53pAnt peptide from its fusion
partner through a highly efficient enzymatic cleavage reac-
tion. Sarkosyl was used to induce mild denaturing effects
on protein structures, so its presence in the cleavage buf-
fer allows maintenance of the fused peptide in solution in
conditions compatible with thrombin activity, and indu-
cing flexibility of protein structures enables exposure of
recognition sites of the enzyme. These reaction conditions
allow a 50% reduction of the amount of thrombin used to
cleave one mg of fused peptide when compared to the rec-
ommendation of the supplier, and the use of at least 20
times less enzyme than the amount used in similar expres-
sion systems [19,20], since, as shown in Figure 3B, the
procedure achieves cleavage of 2 mg of protein per unit of
thrombin in 16 hours.
Although the enzymatic cleavage reaction failed for
KSI-PNC27 protein, this result is not discouraging as it
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bin cleavage site, which provides rigidity to the protein
structure and does not allow proper coupling interaction
of the protease in its recognition site, making the chosen
peptide sequence not suitable for thrombin proteolysis.
It was observed that in the Ni-NTA chromatography
step for after-cleavage peptide purification, the process re-
quires a total protein concentration below 1 mg/mL be-
fore loading the sample onto the column. This step is
conducted in mild denaturing conditions, therefore, not
all the residues of the protein are exposed. This could lead
to different concentration dependent conformations, in
which at higher concentrations, the polyhistidine tag
could not be exposed in all species of the dynamic equilib-
rium or either protein-protein/column-protein interac-
tions could lead to steric hindrance, thus impeding the
proteins to bind to the resin.
There was a loss of about 15% of the p53pAnt peptide
that remains strongly attached to the resin during this
last purification process, probably due to the three his-
tidine residues of the bioactive peptide sequence as it
was not eluted by salt or urea but only with high imid-
azole concentrations. It is postulated that this loss
could vary depending on the histidine residue content
of the target peptide.
Due to the use of thrombin, the system has some
minor restrictions in the first and second amino acid of
the bioactive sequence. As has been described in the lit-
erature [38], they cannot be acidic amino acids and, as
discussed above, it was observed that Pro is also a re-
stricted amino acid in these positions. With these excep-
tions, it is proposed that the system designed could
provide a sustainable and efficient peptide manufactur-
ing process, for almost any peptide sequence, since re-
combinant protein production and purification levels
were very similar for KSI, KSI-p53pAnt and KSI-PNC27.
Hence, the negative result in producing PNC27 peptide
is considered inherent to its amino acid sequence rather
than because of the designed procedure.
As recombinant protein is about 20% of dry cell mass
in all cases, the potential productivity of p53pAnt and
PNC27 was estimated from the relative ratio of the pep-
tides size compared to the sequence of the recombinant
KSI-peptide proteins. The p53pAnt peptide accounts for
23% of the fused peptide, while the PNC27 peptide com-
prises 21% of the recombinant KSI-peptide protein.
Thereby, potential productivity of p53pAnt peptide is
46 mg per g dry cell weight and for PNC27 the calcu-
lated value is 42 mg per g dry cell weight.
From the values shown in Table 1, overall productivity
of p53pAnt was estimated as 37 mg per g dry cell
weight. Experimental results indicate that the overall
productivity of p53pAnt is about 34 mg per g of dry cell
mass, very close to the estimated value. In the case ofPNC27, this estimation could not be done as the cleav-
age reaction was not successful. However, it is postulated
that for the case of a generic peptide, which accounts for
at least 20% of the recombinant KSI-peptide protein,
200 mg of total recombinant protein (KSI-peptide) per g
cell dry weight could be produced. This would result in
potential peptide productivity greater than 40 mg per g
dry cell weight, and after the purification step a final
productivity of over 30 mg per g dry cell weight of puri-
fied peptide. However, it should be noted that the final
value will always depend on the particular properties of
the sequence to be produced, especially, the amino ter-
minal amino acids, which influence the efficiency of en-
zymatic proteolysis, and the number of histidine residues
in the bioactive sequence, which could be important for
peptide purification efficiency.
The peptide productivity obtained is high compared
with that reported in other systems for recombinant
peptide production [14-17,39-41]. The highest reported
productivity was about 20 mg/g of cell [17], and in the
present system, 30 mg of purified peptide per gram of
cell could be obtained.
The cleavage procedure is the limiting step of the
process. To make the process faster, a second dose of en-
zyme could be added at 16 hours of the reaction. On the
other hand, if it is worth sacrificing overall productivity in
exchange for a faster process, the reaction could be
stopped at this time and the final productivity would not
be less than 20 mg of peptide per gram of dry cell mass.
Finally, it was observed that, at different induction
conditions, recombinant protein production remains at
about 20% of the dry cell mass, hence, using fed-batch
cultures of Escherichia coli, which enable obtention of
100 g/l of cells [42] could lead to a productivity of over
3 g/l of peptide.
Conclusions
Recombinant fused peptides were produced as relatively
pure protein in inclusion bodies and were purified by af-
finity chromatography under denaturing conditions. The
urea-denatured protein was recovered by dilution pre-
cipitation and solubilized in a specific mild denaturing
conditions buffer. The procedure designed allows separ-
ation of the peptide p53pAnt and the KSI partner pro-
tein by enzymatic proteolysis with thrombin, in a highly
efficient manner; however, the proteolysis process failed
to release PNC27. The recombinant p53pAnt peptide
was purified from the cleavage product by Ni-NTA affin-
ity chromatography, and recovered in the supernatant
with a high purity, which was estimated to be at least
95%. The designed system has high productivity of more
than 30 mg of purified peptide per gram of dry cell
weight and is suitable for the production of peptides for
scientific research, since it achieves the scale and purity
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peptides research.
Methods
Escherichia coli strains DH5α and BL21(DE3) were used
as hosts for cloning and expression, respectively. The
pGEM-T Easy vector (Promega) was used for cloning
oligonucleotide sequences of the peptides. The pET-31b
(+) vector (Novagen) was used as a template for con-
struction of the modified expression vector pET31HT.
Elongase enzyme (Invitrogen) was used for the PCR
amplification of sequences. Restriction enzymes NdeI,
XhoI, PacI, AvrII (New England Biolabs) and T4 DNA
ligase (Invitrogen) were used according to the recom-
mendation of the supplier. Thrombin, restriction grade,
was purchased from Novagen. Oligonucleotides were
synthesized by Integrated DNA Technologies. For pro-
tein purification, Ni-NTA agarose (QIAGEN) was used.
Proteins and peptides were loaded on SDS-PAGE gels
for analysis, and concentration was determined by the
Bradford assay, using bovine serum albumin as the
standard. Densitometry analysis of SDS-PAGE gels was
done using ImageJ software.
pET31HT expression vector construction
To amplify the KSI sequence from the pET-31b(+) vector
as a template, the following primers were designed and
used: 5′-CATATGCACCACCACCACCACCACCATACC
CCAGAACACA- 3′ and 5′-CTCGAGTTAATTAACCCC
TAGGACCCGCCTGGCATGCGTGAAT- 3′. Thereby,
the hexahistidine tag present in the template was moved
from the C-terminal to the N-terminal of the KSI se-
quence and a thrombin cleavage sequence was introduced
downstream of the KSI gene, followed by an AvrII site and
a PacI site. These restriction enzyme sites allow cloning of
DNA sequences coding potentially therapeutic cell pene-
trating peptides. The NdeI and XhoI cloning sites present
in the original vector flanking the KSI gene, were kept at
the N-terminal and C-terminal, respectively.
The PCR product was cloned into the pGEM-T Easy
vector, and subcloned into pET-31b(+) expression vector
between the NdeI and XhoI restriction enzymes sites.
Cloning of the DNA sequences encoding the peptides
The DNA sequences encoding peptides were synthesized
as two complementary oligonucleotides. The sequences
include AvrII and PacI restriction enzyme sites to facilitate
cloning into the pET31HT expression vector. The peptide-
encoding DNA sequences were designed in order to avoid
codons used with low frequency in Escherichia coli. To
anneal the single strand oligonucleotides, they were heated
at 95°C for 5 minutes, then left in a boiling water bath and
allowed to cool slowly to room temperature. Dimers were
adenylated and cloned into the pGEM-T Easy vector.The final constructs were built from the sequences
cloned into the pGEM-T Easy vector and the pET31HT
expression vector, through the AvrII and PacI restriction
enzyme sites.
The constructed plasmids pET31HT, pET31HT-p53pAnt
and pET31HT-PNC27 were sequenced by Macrogen
(Korea) and transformed into Escherichia coli BL21(DE3)
electrocompetent cells.
Production and purification of fused peptides
Escherichia coli BL21(DE3) harboring the expression
vectors were cultivated in LB medium containing 100
μg/ml ampicillin, at 37°C with shaking. The overnight
cultures were used to inoculate 100 ml LB media (with
100 μg/ml ampicillin) to an initial OD600 = 0.05, and
grown at 37°C with shaking. When OD600 of the cultures
reached 0.6, IPTG was added to a final concentration of
1 mM. After 3–6 h induction, cells were harvested by
centrifugation, resuspended in binding buffer (40 mM
Tris, 500 mM NaCl, 15 mM Imidazole, pH 8.0), and
lysed by sonication in an ice-water bath. The suspen-
sions were centrifuged (10,000 x g, 10 min) to pellet the
insoluble matter, and the pellets were resuspended in de-
naturing binding buffer (8 M Urea) and centrifuged
again. The supernatants were incubated on a rotary
shaker with Ni-NTA agarose at 4°C for 60 min. Then,
the columns were packed and washed with denaturing
binding buffer and the fused peptides were eluted with
elution buffer (40 mM Tris, 500 mM NaCl, 300 mM
Imidazole, 8 M Urea, pH 8.0).
Proteolytic cleavage and purification of recombinant peptides
Purified fused peptides in elution buffer (8 M Urea) were
precipitated by rapid dilution with dilution buffer
(40 mM Tris, pH 8.0) and collected by centrifugation at
5,000 × g for 10 min. The pellets were resuspended in
cleavage buffer (20 mM Tris, 150 mM NaCl, pH 8.0,
0.3% sarkosyl). Thrombin was added to the samples and
incubated at 23°C on a rotary shaker. Peptides were
batch purified from the digestion product by affinity re-
tention of the fusion partner on Ni-NTA agarose. Puri-
fied samples were stored at −20°C.
MALDI-TOF mass spectrometry was used to analyze
the resultant peptide. Samples were diluted with formic
acid 0.1% and methanol 3% and mixed with α-cyano-4-
hydroxycinnamic acid (CHCA matrix). The spectrum
was obtained in positive linear mode.
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